Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA CLEARS 53 NMEs IN 1996 -- AVERAGE APPROVAL TIME IS 20.5; NEUROPHARM DRUGS APPEAR READY FOR 1997 CLEARANCE: THREE PARKINSON's THERAPIES POISED FOR APPROVAL

Executive Summary

Three Parkinson's disease therapies appear on track for approval in 1997, continuing the prominence of central nervous system drugs among products reaching the commercial stage.

You may also be interested in...



US FDA Blows Past Novel Approvals Record On Way To Unprecedented Year For New Drugs

Roche’s Xofluza brings novel approval count for CDER to 47, topping 2017's record – and FDA still has at least 14 novel agents under review with 2018 goal dates.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Latest News
See All
UsernamePublicRestriction

Register

PS029380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel